NX-1607

N/A

Report date: 2025/02/07 16:24:20
NMEFirst In Class

Base Information

Drug NameNX-1607
Drug Alias NameNX-1607
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionE3 ubiquitin-protein ligase CBL-B inhibitors
TargetsE3 ubiquitin-protein ligase CBL-B
Therapy Area/IndicationsRichter's SyndromeProstatic Neoplasms, Castration-ResistantUterine Cervical Neoplasms +[14] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNurix Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesNurix Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsRichter's SyndromeProstatic Neoplasms, Castration-ResistantUterine Cervical Neoplasms +[14] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A